Economic analysis of antibiotic regimens used in the treatment pharyngitis: A prospective comparison of azithromycin versus roxithromycin

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. C, 1996, Pages 151-161

  Carbon, C ^a   Hotton, J M ^b   Pepin L F ^b   Wohlhuter, C ^b   Souetre E ^c   Hardens, M ^d   Lozet, H ^c   Riviera, M ^c  

^a BICHAT HOSPITAL   (France)

^b PFIZER INC   (United States)

^c Benefit Research Group   (France)

^d Benefit Research Group   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; ROXITHROMYCIN;

ABSENTEEISM; ADULT; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DYSPEPSIA; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

EID: 0029816170     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_c.151     Document Type: Article

References (28)

1. Canadian Coordination Office for Health Technology Assessment. (1994). Guidelines for Economic Evaluation of Pharmaceuticals. CCOHTA, Ottawa.
2. de Melker, R. A. & Kuyvenhoven, M. M. (1991). Management of upper respiratory tract infection in Dutch general practice. British Journal of General Practice 41, 504-7.
3. Drummond, M. & Davis, L. (1992). Economic evaluation alongside clinical trials: revisiting the issues. International Journal of Health Technology Assessment 23, 445-56.
4. Eisen, S. A., Miller, D. K., Woodward, R. S., Spitznagel, E. & Przybeck, T. R. (1990). The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine 150, 1881-4.
5. Eisenberg, J. M. (1989). A guide to the economics analysis of clinical practices. Journal of the American Medical Association 262, 2879-86.
6. Finch, R. G. (1990). Epidemiological features and chemotherapy of community-acquired respiratory tract infections. Journal of Antimicrobial Chemotherapy 26, Suppl. E, 53-61.
7. Gerber, M. A., Randolph, M. R., Chanatry, J., Wright, L. L., Anderson, L. E. & Kaplan, E. L. (1986). Once daily therapy for streptococcal pharyngitis with cefadroxil. Journal of Pediatrics 109, 531-7.
8. Gerber, M. A., Randolph, M. R., Chanatry, J., Wright, L. L, de Meo, K. & Kaplan, E. L. (1987). Five vs. ten days of penicillin V therapy for streptococcal pharyngitis. American Journal of Disease Control 141, 224-7.
9. Hoffman, S. (1986). Incidence and management of sore throat in general practice. Scandinavian Journal of Primary Health Care 4, 143-50.
10. Holmberg, S. D. & Faich, G. A. (1983). Streptococcal pharyngitis and acute rheumatic fever in Rhode Island. Journal of the American Medical Association 250, 2307-12.
11. Hoolon, T. M. (1991). A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. American Journal of Medicine 91, Suppl. 3, 23-6.
12. Kruse, W. (1989). Continuous compliance monitoring: its utility for interpretation of drug trials. European Journal of Clinical Pharmacology 36, 289-94.
13. Mäkelaä, M. & Sintonen, H. (1991). Rationality and cost-effectiveness of diagnosis and treatment of group A streptococci in primary care patients with pharyngitis. Scandinavian Journal of Infectious Diseases 23, 47-53.
14. Milatovic, D. & Knauer, J. (1989). Cefadroxil versus penicillin in the treatment of streptococcal tonsillopharyngitis. European Journal of Clinical Microbiology and Infectious Diseases 8, 282-8.
15. Müller, O. (1993). Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 137-46.
16. Pankey, G. A., Gleason, C., File, T. M. & Brown, W. (1981). A comparative study of bacampicillin hydrochloride, penicillin V, and amoxicillin in the treatment of acute tonsillitis and/or pharyngitis due to β-hemolytic streptococci. Reviews of Infectious Diseases 3, 154-8.
17. Pichichero, M. E. (1990). Controversies in the treatment of streptococcal pharyngitis. American Family Physician 42, 1567-76.
18. Pichichero, M. E. (1993). Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatric Infectious Disease Journal 12, 263-74.
19. Poses, R. M., Wigton, R. S., Cebull, R. D., Center, R. M. & Collins, M. et al. (1993). Practice variation in the management of pharyngitis. Medical Decision Making 13, 293-301.
20. Reed, B. D., Huck, W. & Zazove, P. (1991). Treatment of β-hemolytic streptococcal pharyngitis with cefaclor or penicillin. Journal of Family Practice 32, 138-44.
21. Schwartz, R. H., Wientzen, R. L., Pedreira, F., Feroli, E. J., Mella, G. W. & Guandolo, V. L. (1981). Penicillin V for group A streptococcal pharyngotonsillitis: a randomized trial of seven versus ten days' therapy. Journal of the American Medical Association 246, 1790-5.
22. Shvartzman, P. (1994). Careful prescribing is beneficial. British Medical Journal 309, 1011-2.
23. Shvartzman, P., Tabenkin, H., Rosentzwaig, A. & Dolginov, S. (1993). Treatment of streptococcal pharyngitis with amoxycillin once a day. British Medical Journal 306, 1170-2.
24. Smith, D. L. & Brauer, W. A. (1981). Comparative costs of diagnosis and treatment in acute pharyngitis. Southern Medical Journal 74, 332-4.
25. Souêtre, E., Hardens, M. & Qing, W. (1994). Economic evaluation of pharmaceuticals: methodological issues. Funding In Clinical Pharmacology 12, 234-9.
26. Touw-Otten, F. W. & Johansen, K. S. (1977). Diagnosis, antibiotic treatment and outcome of acute tonsillitis; report of WHO regional office for European study in 17 European countries. Family Practice 9, 255-62.
27. Union des Caisses Nationales de Sécurité Sociale. (1992). Nomenclature générale des actes professionels. UCANSS, Paris.
28. Young, R. A., Gonzalez, J. P. & Sorkin, E. M. (1989). Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37, 8-41.